ET RePharma Summit 2026, Mumbai – 13 Feb 2026
CLINEXEL participated in the 6th edition of ET RePharma Summit 2026, held in Mumbai on 13 February 2026, where industry leaders discussed the future of pharmaceutical innovation, clinical research, and innovative product development in India.
During the summit, CLINEXEL’s CSO, Dr. Mukesh Kumar, M.D., highlighted the acceleration of innovative product development in India and the role CLINEXEL plays in advancing the clinical research ecosystem from Phase 1 (FIM) clinical trials to Phase 3 clinical trials, along with global clinical strategy and risk optimization.
CLINEXEL CEO, Dr. Deepa Arora, also shared her strong commitment to supporting emerging biotechnology companies with a major focus on:
- Antimicrobial Resistance (AMR)
- Oncology clinical research
Dr. Mukesh Kumar further reflected on the significant progress made over the last year, including:
- Indian companies filing with the US FDA
- Approvals for new indications
- Advancements in complex therapies such as CAR-T
He also emphasized that while several milestones are now visible, substantial work continues behind the scenes in:
- Early-stage research
- Clinical development
- Regulatory strategy
- Innovative therapy development
CLINEXEL continues to support pharmaceutical and biotechnology companies through scientifically driven clinical research, regulatory expertise, and globally aligned clinical development strategies focused on accelerating innovation while maintaining high standards of quality and compliance.